Bayer


Dividend cut to the minimal amount as last line of defence

19/02/24 -"Bayer has announced a dividend cut to the legally-required minimum of 4% of AG capital, which translates to a dividend proposal of 11 euro cents (2022: €2.40 – consensus: €1.92) at the AGM on 26 ..."

Pages
75
Language
English
Published on
19/02/24
You may also be interested by these reports :
11/11/26
The Q3 profitability materially surpassed expectations, backed by the strong momentum for migraine and depression/schizophrenia treatments. The ...

06/11/26
Genmab’s sales missed expectations, but profitability significantly exceeded expectations. Growth was driven by contributions from most offerings, ...

06/11/26
Sanofi’s growth in recent years has been single-handedly driven by its cornerstone immunology treatment Dupixent, though there has been some support ...

06/11/26
Novonesis delivered an in-line Q3 26, with revenue and adjusted EBITDA marginally ahead of consensus. Food & Beverages (F&B) accelerated to 14%, ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO